De Aquino Awarded IMPOWR-YOU Grant to Study Pain Sensitivity, Opioid Use Disorder
Joao P. De Aquino, MD, assistant professor of psychiatry, has been awarded a pilot grant from the Integrative Management of Chronic Pain and Opioid Use Disorder for Whole Recovery-Yale and Organizations United (IMPOWR-YOU) Research Center to evaluate the relationship between pain sensitivity and brain synaptic density among people with opioid use disorder (OUD).
Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study
COVID-19 patients with substance use disorders had greater likelihood of requiring critical interventions, such as ICU admission and ventilatory support. Substance use disorders and psychiatric diagnoses were also associated with a longer duration of hospitalization and greater number of hospital admissions.Source: The Journal of Clinical Psychiatry
Yale Scientists Identify Genetic Risk Factors for Opioid Use and Related Substance Use Disorders
A new human genomics study led by Yale scientists has identified genetic risk factors for opioid use disorder (OUD) and related substance use disorders according to a new large-scale genome-wide association study – increasing the number of risk genes known from 1 to 19.
WHRY Funds Studies on Heart Disease, Insomnia, and Pain
Women’s Health Research at Yale today announced funding for three new studies investigating a method for improving the diagnosis of heart disease in women, a therapy for clinically significant sleep disruption common in Black women, and the influence of biological sex on the underlying brain patterns that link pain and opioid use.
Addiction Psychiatry Division Will Participate in Consortium to Develop New Treatment Tools for Addiction
Yale School of Medicine’s Division of Addiction Psychiatry will participate in a consortium funded by a multimillion-dollar federal grant that will attempt to develop new treatment tools for addiction.
Op-Ed: Yale study on lung disease forecasts dire consequences for flavor bans
A new study from Yale School of Public Health should serve as a warning to e-cigarette opponents and public health officials pushing e-cigarette flavor bans and restrictions around the country. The Yale research revealed that higher levels of e-cigarette and marijuana use did not result in higher rates of e-cigarette or vaping-related lung injuries (EVALI). EVALI made headlines during 2019 and was responsible for at least 2,800 hospitalizations and 68 deaths.Source: The Center Square
Large Genetic Study Expands Links Between DNA Variations and Problematic Drinking
A genome-wide analysis of over 435,000 individuals of European ancestry has revealed 19 new locations in the human genome where common DNA variations significantly raise risk for problematic drinking. It also linked pathological drinking with elevated risk of many psychiatric disorders, including depression and schizophrenia.Source: Brain & Behavior Research Foundation
WHRY Funds Studies on Stroke, Endometrial Cancer, and Addiction to Opioids
Women’s Health Research at Yale today announced funding for three studies investigating sex differences in stroke, endometrial cancer, and alternate pain relief for women recovering from past opioid use who are giving birth via cesarean section.
Yale Scientists Awarded $8.4M Grant to Develop Treatments for Women With Problem Drinking
Yale Department of Psychiatry scientists have been awarded a five-year, $8.4 million federal grant to establish a new research center at Yale that will develop treatments to help women with problem drinking.
Are Benzodiazepines the New Opioids?
Yale addiction specialists believe the primary care system can play a key role in preventing another medication epidemic. David A. Fiellin, MD, worries that otherwise, the trajectory of benzodiazepine prescriptions might lead to a situation that resembles the opioid crisis.Source: Yale Medicine
Yale Investigators' Lead Grant Awarded as Part of the NIH HEAL Initiative on Opioids
Dr. Gail D’Onofrio, Professor of Emergency Medicine and Public Health and Dr. David Fiellin, Professor of Medicine, Emergency Medicine and Public Health are lead investigators in a $25.5 Million study being conducted by the National Drug Abuse Treatment Clinical Trials Network’s New England Consortium Node.